An observational study in Covid19, sponsored by Colorado State University. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-21.
Sponsored by Colorado State University · Observational
The NoCo-CoBio Project is a biobanking effort to store and preserve saliva, nasopharyngeal, stool and blood specimens from SARS-CoV-2 PCR (polymerase chain reaction) positive individuals.
The investigators have created a biorepository of stool, saliva, nasopharyngeal swab specimens, peripheral blood mononuclear cells, serum, and plasma from SARS-CoV-2 infected individuals for research purposes. The multifaceted biorepository will be used to establish markers predicting various presentations of COVID-19 (coronavirus disease 2019).
7,774 studies on the registry are indexed under COVID-19; 482 are open to participants now.
This study's enrollment of 148 is below the median of 260 across 3,188 observational studies indexed under COVID-19.
Browse COVID-19 studies →Colorado State University is the lead sponsor of 116 studies on the registry; 20 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
The investigators aim to enroll individuals who have had a positive SARS-CoV-2 PCR, with a goal of enrolling 100 hospitalized patients with acute SARS-CoV-2 infection, as well as 100 convalescent participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with an acute SARS-CoV-2 infection. Intervention will not be implemented in this study.
Participants with a previous diagnosis of SARS-CoV-2 infection, now in the convalescent phase of disease. Intervention will not be implemented in this study.
Evaluation of parameters for markers of SARS-CoV-2 infection and predictors for severe disease
Evaluation of parameters for markers of SARS-CoV-2 infection and predictors for severe disease
Time frame: 6 months
Evaluation of markers and predictors of post acute sequelae of COVID-19
Evaluation of markers and predictors of post acute sequelae of COVID-19
Time frame: 2 years
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.